Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) shares hit a new 52-week high on Friday . The company traded as high as $11.50 and last traded at $11.25, with a volume of 2078657 shares changing hands. The stock had previously closed at $9.65.

Wall Street Analyst Weigh In

Several research firms have recently commented on PSNL. BTIG Research reissued a “buy” rating and issued a $12.00 price target on shares of Personalis in a report on Friday, January 9th. Needham & Company LLC increased their price objective on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. HC Wainwright raised their target price on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Guggenheim boosted their target price on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Personalis in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.57.

Personalis Stock Down 9.6%

The company has a market cap of $903.10 million, a price-to-earnings ratio of -11.56 and a beta of 1.96. The company has a fifty day simple moving average of $9.06 and a two-hundred day simple moving average of $7.47.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. On average, research analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 134,481 shares of company stock valued at $1,397,564. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of Personalis during the 2nd quarter worth $30,000. Ameritas Investment Partners Inc. purchased a new stake in Personalis during the second quarter valued at about $34,000. BNP Paribas Financial Markets increased its stake in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Alpha Wealth Funds LLC purchased a new position in shares of Personalis in the 2nd quarter worth about $66,000. Finally, Farther Finance Advisors LLC purchased a new position in shares of Personalis in the 3rd quarter worth about $66,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.